Uncategorized
Usher syndrome candidate designated orphan drug
An investigational drug from ProQR for the treatment of retinitis pigmentosa associated with Usher syndrome has received orphan drug designation from the FDA and the European Medicines Agency, according to a company press release.QRX-411 targets the pseudo-exon 40 mutation in the USH2A gene and has shown promising preclinical data in mRNA restoration, the release said.